SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Brancati FL, Kao WHL, Folsom AR, Watson RL, Szklo M. Incident type 2 diabetes mellitus in African American and white adults: the Atherosclerosis Risk in Communities Study. JAMA 2000; 283: 22532259.
  • 2
    Carnethon MR, Palaniappan LP, Burchfiel CM, Brancati FL, Fortmann SP. Serum insulin, obesity, and the incidence of type 2 diabetes in black and white adults: the Atherosclerosis Risk in Communities study: 1987–1998. Diabetes Care 2002; 25: 13581364.
  • 3
    Bonora E, Kiechl S, Willeit J et al. Population-based incidence rates and risk factors for type 2 diabetes in white individuals: the Bruneck Study. Diabetes 2004; 53: 17821789.
  • 4
    Sullivan PW, Morrato EH, Ghushchyan V, Wyatt HR, Hill JO. Obesity, inactivity, and the prevalence of diabetes and diabetes-related cardiovascular comorbidities in the US, 2000–2002. Diabetes Care 2005; 28: 15991603.
  • 5
    Schmidt MI, Duncan BB, Sharrett AR et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities Study): a cohort study. Lancet 1999; 353: 16491652.
  • 6
    Festa A, D'Agostino R Jr., Tracy RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes 2002; 51: 11311137.
  • 7
    Meigs JB, Hu FB, Rifai N, Manson JE. Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA 2004; 291: 19781986.
  • 8
    Meigs JB, O'Donnell CJ, Tofler GH et al. Haemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: The Framingham Offspring Study. Diabetes 2006; 55: 530537.
  • 9
    Stern MP, Morales PA, Valdez RA et al. Predicting diabetes. Moving beyond impaired glucose tolerance. Diabetes 1993; 42: 706714.
  • 10
    Stranges S, Trevisan M, Dorn JM, Dmochowski J, Donahue RP. Body fat distribution, liver enzymes, and risk of hypertension: evidence from the Western New York Study. Hypertension 2005; 46: 11861193.
  • 11
    Donahue RP, Rejman K, Rafalson LB et al. Sex differences in endothelial function markers prior to conversion to pre-diabetes: does the clock start ticking earlier among women? The Western New York Study. Diabetes Care 2007; 30: 354359.
  • 12
    Donahue RP, Stranges S, Rejman K et al. Elevated cystatin-C concentration is associated with progression to pre-diabetes: the Western New York Study. Diabetes Care 2007; 30: 16.
  • 13
    The Expert Committee on the Diagnosis and Classification. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 11831197.
  • 14
    Sakkinen PA, Macy EM, Callas PW et al. Analytical and biologic variability in measures of hemostasis, fibrinolysis, and inflammation: assessment and implications for epidemiology. Am J Epidemiol 1999; 149: 261267.
  • 15
    DeClerck P, Alessi M, Verstreken M et al. Measurement of plasminogen activator inhibitor 1 (PAI-1) in biological fluids with a murine monoclonal antibody based enzyme-linked immunosorbent assay. Blood 1988; 71: 220225.
  • 16
    Matthews DR, Hosker JP, Rudenski AS et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting glucose and insulin concentrations in man. Diabetologia 1985; 28: 412419.
  • 17
    DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44: 837845.
  • 18
    Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 2007; 115: 928935.
  • 19
    Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286: 327334.
  • 20
    Barzilay JI, Abraham L, Heckbert SR et al. The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes 2001; 50: 23842389.
  • 21
    Freeman DJ, Norrie J, Caslake MJ et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002; 51: 15961600.
  • 22
    Han TS, Sattar N, Williams K et al. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 2002; 25: 20162021.
  • 23
    Thorand B, Lowel H, Schneider A et al. C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984–1998. Arch Intern Med 2003; 163: 9399.
  • 24
    Spranger J, Kroke A, Mohlig M et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC) Potsdam Study. Diabetes 2003; 52: 812817.
  • 25
    Duncan BB, Schmidt MI, Pankow JS et al. Low-grade systemic inflammation and the development of type 2 diabetes: the Atherosclerosis Risk in Communities Study. Diabetes 2003; 52: 17991805.
  • 26
    Nakanishi S, Yamane K, Kamei N, Okubo M, Kohno N. Elevated C-reactive protein is a risk factor for the development of type 2 diabetes in Japanese Americans. Diabetes Care 2003; 26: 27542757.
  • 27
    Hu FB, Meigs JB, Li TY, Rifai N, Manson JE. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 2004; 53: 693700.
  • 28
    Doi Y, Kiyohara Y, Kubo M et al. Elevated C-reactive protein is a predictor of the development of diabetes in a general Japanese population: the Hisayama Study. Diabetes Care 2005; 28: 24972500.
  • 29
    Ford ES. Body mass index, diabetes, and C-reactive protein among U.S. adults. Diabetes Care 1999; 22: 19711977.
  • 30
    Festa A, D'Agostino R Jr., Howard G et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 4247.
  • 31
    Greenberg AS, Obin MS. Obesity and the role of adipose tissue in inflammation and metabolism. Am J Clin Nutr 2006; 83: 461S465S.
  • 32
    Kuller LH, Eichner JE, Orchard TJ et al. The relation between serum albumin levels and risk of coronary heart disease in the Multiple Risk Factor Intervention Trial. Am J Epidemiol 1991; 134: 12661277.
  • 33
    Folsom AR, Ma J, Eckfeldt JH et al. Low serum albumin: association with diabetes mellitus and other cardiovascular risk factors but not with prevalent cardiovascular disease or carotid artery intima-media thickness: the Atherosclerosis Risk in Communities (ARIC) Study Investigators. Ann Epidemiol 1995; 5: 186191.
  • 34
    Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998; 279: 14771482.
  • 35
    Djousse L, Rothman KJ, Cupples LA, Levy D, Ellison RC. Serum albumin and risk of myocardial infarction and all-cause mortality in the Framingham offspring study. Circulation 2002; 106: 29192924.
  • 36
    Vozarova B, Weyer C, Lindsay RS et al. High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 2002; 51: 455461.
  • 37
    Petitti DB, Kipp H. The leukocyte count: associations with intensity of smoking and persistence of effect after quitting. Am J Epidemiol 1986; 123: 8995.
  • 38
    Duncan BB, Schmidt MI, Offenbacher S et al. Factor VIII and other hemostasis variables are related to incident diabetes in adults: the Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care 1999; 22: 767772.
  • 39
    Thorand B, Baumert J, Chambless L et al. Elevated markers of endothelial dysfunction predict type 2 diabetes mellitus in middle-aged men and women from the general population. Arterioscler Thromb Vasc Biol 2006; 26: 398405.
  • 40
    Rossi R, Cioni E, Nuzzo A et al. Endothelial-dependent vasodilation and incidence of type 2 diabetes in a population of healthy postmenopausal women. Diabetes Care 2005; 28: 702707.
  • 41
    Krakoff J, Funahashi T, Stehouwer CD et al. Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care 2003; 26: 17451751.
  • 42
    Lindsay RS, Funahashi T, Hanson RL et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002; 360: 5758.
  • 43
    Daimon M, Oizumi T, Saitoh T et al. Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese population: the Funagata study. Diabetes Care 2003; 26: 20152020.
  • 44
    Spranger J, Kroke A, Mohlig M et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003; 361: 226228.
  • 45
    Snehalatha C, Mukesh B, Simon M et al. Plasma adiponectin is an independent predictor of type 2 diabetes in Asian Indians. Diabetes Care 2003; 26: 32263229.
  • 46
    Duncan BB, Schmidt MI, Pankow JS et al. Adiponectin and the development of type 2 diabetes: the Atherosclerosis Risk in Communities Study. Diabetes 2004; 53: 24732478.
  • 47
    Park PJ, Griffin SJ, Sargeant L, Wareham NJ. The performance of a risk score in predicting undiagnosed hyperglycemia. Diabetes Care 2002; 25: 984988.
  • 48
    Glumer C, Carstensen B, Sandbaek A et al. A Danish diabetes risk score for targeted screening: the Inter99 study. Diabetes Care 2004; 27: 727733.
  • 49
    Heldgaard PE, Griffin SJ. Routinely collected general practice data aids identification of people with hyperglycaemia and metabolic syndrome. Diabet Med 2006; 23: 9961002.
  • 50
    Pepe MS. The Statistical Evaluation of Medical Tests for Classification and Prediction. Oxford Statistical Series 28. Oxford University Press: New York, 2004.